Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:KRAS-SLC2A14

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: KRAS-SLC2A14
	FusionPDB ID: 43436
	FusionGDB2.0 ID: 43436
		Hgene	Tgene
	Gene symbol	KRAS	SLC2A14
	Gene ID	3845	144195
	Gene name	KRAS proto-oncogene, GTPase	solute carrier family 2 member 14
	Synonyms	'C-K-RAS\|C-K-RAS\|CFC2\|K-RAS2A\|K-RAS2B\|K-RAS4A\|K-RAS4B\|K-Ras\|K-Ras 2\|KI-RAS\|KRAS1\|KRAS2\|NS\|NS3\|OES\|RALD\|RASK2\|c-Ki-ras\|c-Ki-ras2	GLUT14\|SLC2A3P3
	Cytomap	12p12.1	12p13.31
	Type of gene	protein-coding	protein-coding
	Description	GTPase KRasK-ras p21 proteinKirsten rat sarcoma viral oncogene homologKirsten rat sarcoma viral proto-oncogenePR310 c-K-ras oncogenec-Kirsten-ras proteincellular c-Ki-ras2 proto-oncogenecellular transforming proto-oncogeneoncogene KRAS2transformi	solute carrier family 2, facilitated glucose transporter member 14glucose transporter type 14solute carrier family 2 (facilitated glucose transporter), member 14solute carrier family 2 (facilitated glucose transporter), member 3 pseudogene 3
	Modification date	20200329	20200313
	UniProtAcc	P01116 Main function of 5'-partner protein: FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity (PubMed:20949621). Plays an important role in the regulation of cell proliferation (PubMed:23698361, PubMed:22711838). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner (PubMed:24623306). {ECO:0000269\|PubMed:20949621, ECO:0000269\|PubMed:22711838, ECO:0000269\|PubMed:23698361, ECO:0000269\|PubMed:24623306, ECO:0000305}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000256078, ENST00000311936, ENST00000556131, ENST00000557334,	ENST00000535295, ENST00000539924, ENST00000542546, ENST00000396589, ENST00000542505, ENST00000544749, ENST00000340749, ENST00000431042, ENST00000543909,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 2 X 5=60	6 X 5 X 4=120
	# samples	6	6
	** MAII score	log2(6/60*10)=0	log2(6/120*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: KRAS [Title/Abstract] AND SLC2A14 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: KRAS [Title/Abstract] AND SLC2A14 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	KRAS(25398208)-SLC2A14(7985410), # samples:1
Anticipated loss of major functional domain due to fusion event.	KRAS-SLC2A14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. KRAS-SLC2A14 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	SLC2A14	GO:0070837	dehydroascorbic acid transport	28971850
Tgene	SLC2A14	GO:1904659	glucose transmembrane transport	28971850

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:25398208/chr12:7985410)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across KRAS (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across SLC2A14 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000311936	KRAS	chr12	25398208	-	ENST00000340749	SLC2A14	chr12	7985410	-	3583	303	183	1778	531
ENST00000311936	KRAS	chr12	25398208	-	ENST00000543909	SLC2A14	chr12	7985410	-	3581	303	183	1778	531
ENST00000311936	KRAS	chr12	25398208	-	ENST00000431042	SLC2A14	chr12	7985410	-	3576	303	183	1778	531
ENST00000557334	KRAS	chr12	25398208	-	ENST00000340749	SLC2A14	chr12	7985410	-	3588	308	188	1783	531
ENST00000557334	KRAS	chr12	25398208	-	ENST00000543909	SLC2A14	chr12	7985410	-	3586	308	188	1783	531
ENST00000557334	KRAS	chr12	25398208	-	ENST00000431042	SLC2A14	chr12	7985410	-	3581	308	188	1783	531
ENST00000256078	KRAS	chr12	25398208	-	ENST00000340749	SLC2A14	chr12	7985410	-	3455	175	55	1650	531
ENST00000256078	KRAS	chr12	25398208	-	ENST00000543909	SLC2A14	chr12	7985410	-	3453	175	55	1650	531
ENST00000256078	KRAS	chr12	25398208	-	ENST00000431042	SLC2A14	chr12	7985410	-	3448	175	55	1650	531

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000311936	ENST00000340749	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000498595	0.99950135
ENST00000311936	ENST00000543909	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000502041	0.9994979
ENST00000311936	ENST00000431042	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000511507	0.9994885
ENST00000557334	ENST00000340749	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.00049765	0.9995023
ENST00000557334	ENST00000543909	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000501085	0.99949884
ENST00000557334	ENST00000431042	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000510517	0.9994894
ENST00000256078	ENST00000340749	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000420406	0.9995796
ENST00000256078	ENST00000543909	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.000422263	0.9995777
ENST00000256078	ENST00000431042	KRAS	chr12	25398208	-	SLC2A14	chr12	7985410	-	0.00043032	0.9995697

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for KRAS-SLC2A14

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
KRAS	chr12	25398208	SLC2A14	chr12	7985410	175	40	QNHFVDEYDPTIEVTPALIFAITVAT
KRAS	chr12	25398208	SLC2A14	chr12	7985410	303	40	QNHFVDEYDPTIEVTPALIFAITVAT
KRAS	chr12	25398208	SLC2A14	chr12	7985410	308	40	QNHFVDEYDPTIEVTPALIFAITVAT

Top

Potential FusionNeoAntigen Information of KRAS-SLC2A14 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

KRAS-SLC2A14_25398208_7985410.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B45:01	DEYDPTIEV	0.9985	0.851	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:02	DEYDPTIEV	0.9961	0.5962	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:01	IEVTPALIF	0.9949	0.9066	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B14:01	DEYDPTIEV	0.9867	0.7169	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B14:02	DEYDPTIEV	0.9867	0.7169	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:03	IEVTPALIF	0.9792	0.8885	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:01	DEYDPTIEV	0.9672	0.963	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:03	DEYDPTIEV	0.8683	0.9795	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B15:37	DEYDPTIEV	0.8017	0.7825	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B41:01	DEYDPTIEV	0.7878	0.8191	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:01	DEYDPTIEV	0.7002	0.6998	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B52:01	DEYDPTIEV	0.6884	0.9601	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:13	DEYDPTIEV	0.4439	0.9371	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:06	DEYDPTIEV	0.3597	0.8022	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B15:10	DEYDPTIEV	0.1762	0.7494	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B15:03	IEVTPALIF	0.1468	0.7692	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:02	VDEYDPTIEV	0.9823	0.5903	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B45:01	VDEYDPTIEV	0.9801	0.8371	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:02	DEYDPTIEVT	0.935	0.5912	5	15
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:03	DPTIEVTPAL	0.9238	0.8637	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:01	VDEYDPTIEV	0.8963	0.713	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B41:01	VDEYDPTIEV	0.853	0.8486	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:04	DPTIEVTPAL	0.8155	0.946	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:02	DPTIEVTPAL	0.8155	0.946	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:01	IEVTPALIFA	0.7211	0.5586	11	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:03	TIEVTPALIF	0.6789	0.9364	10	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B45:01	DEYDPTIEVTP	0.9993	0.8921	5	16
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:21	FVDEYDPTIEV	0.9992	0.6139	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:11	FVDEYDPTIEV	0.9988	0.5323	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:02	DEYDPTIEVTP	0.9986	0.5963	5	16
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:35	FVDEYDPTIEV	0.998	0.5288	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:04	FVDEYDPTIEV	0.9978	0.5414	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:16	FVDEYDPTIEV	0.9964	0.5387	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:13	FVDEYDPTIEV	0.9919	0.5547	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:10	EYDPTIEV	0.9999	0.6186	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:07	EYDPTIEV	0.9999	0.6294	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:14	EYDPTIEV	0.9849	0.6388	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B40:06	DEYDPTIEV	0.9993	0.6803	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B54:01	DPTIEVTPA	0.9685	0.5082	8	17
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B73:01	DEYDPTIEV	0.9113	0.6244	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B78:01	DPTIEVTPA	0.825	0.6466	8	17
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B51:07	DEYDPTIEV	0.6556	0.9034	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:09	DEYDPTIEV	0.3433	0.5438	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:05	DEYDPTIEV	0.3092	0.9243	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:12	DEYDPTIEV	0.251	0.9437	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B40:06	VDEYDPTIEV	0.965	0.7668	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:12	DPTIEVTPAL	0.8155	0.946	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:10	DPTIEVTPAL	0.608	0.8899	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C08:15	FVDEYDPTIEV	1	0.9637	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C05:09	FVDEYDPTIEV	1	0.9542	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:06	FVDEYDPTIEV	0.9995	0.855	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:07	FVDEYDPTIEV	0.9993	0.5224	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C02:06	FVDEYDPTIEV	0.9877	0.9854	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B40:06	FVDEYDPTIEV	0.9828	0.8247	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C08:04	FVDEYDPTIEV	0.9054	0.9684	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C08:13	FVDEYDPTIEV	0.9054	0.9684	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C08:03	FVDEYDPTIEV	0.8454	0.9727	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C18:01	EYDPTIEV	0.9999	0.6476	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:01	EYDPTIEV	0.9999	0.6294	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:04	EYDPTIEV	0.996	0.8454	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C07:04	EYDPTIEV	0.9381	0.8741	6	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B40:04	DEYDPTIEV	0.9966	0.7877	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:04	IEVTPALIF	0.9966	0.9162	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:07	IEVTPALIF	0.9956	0.8793	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:06	IEVTPALIF	0.9953	0.9114	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:05	IEVTPALIF	0.9949	0.9066	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:08	IEVTPALIF	0.9945	0.8853	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:03	IEVTPALIF	0.9918	0.9006	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B40:04	IEVTPALIF	0.9864	0.5959	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:07	IEVTPALIF	0.9792	0.8885	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:26	IEVTPALIF	0.9792	0.8885	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:13	IEVTPALIF	0.9792	0.8885	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:07	DEYDPTIEV	0.9781	0.9396	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:04	DEYDPTIEV	0.9749	0.9671	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:05	DEYDPTIEV	0.9672	0.963	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:06	DEYDPTIEV	0.9653	0.9647	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:08	DEYDPTIEV	0.9642	0.9391	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:03	DEYDPTIEV	0.9632	0.9601	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B41:03	DEYDPTIEV	0.9124	0.5362	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:26	DEYDPTIEV	0.8683	0.9795	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:13	DEYDPTIEV	0.8683	0.9795	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:07	DEYDPTIEV	0.8683	0.9795	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:11	IEVTPALIF	0.7876	0.8606	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B78:02	DPTIEVTPA	0.762	0.7978	8	17
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:04	DEYDPTIEV	0.7002	0.6998	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:05	DEYDPTIEV	0.7002	0.6998	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B18:11	DEYDPTIEV	0.689	0.9435	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A69:01	PTIEVTPAL	0.5636	0.5289	9	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:11	DEYDPTIEV	0.5458	0.6538	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:28	IEVTPALIF	0.4235	0.8484	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:31	DEYDPTIEV	0.346	0.9374	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B39:02	DEYDPTIEV	0.3142	0.9403	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B41:03	IEVTPALIF	0.2741	0.5018	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B15:53	IEVTPALIF	0.2065	0.872	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B48:02	IEVTPALIF	0.2005	0.8267	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B15:09	DEYDPTIEV	0.1154	0.6535	5	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B15:54	IEVTPALIF	0.0988	0.8505	11	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:04	VDEYDPTIEV	0.8963	0.713	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:05	VDEYDPTIEV	0.8963	0.713	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:24	DPTIEVTPAL	0.8266	0.8653	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B35:09	DPTIEVTPAL	0.8155	0.946	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B40:04	VDEYDPTIEV	0.7873	0.7674	4	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:05	IEVTPALIFA	0.7211	0.5586	11	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B50:04	IEVTPALIFA	0.7211	0.5586	11	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:07	TIEVTPALIF	0.6789	0.9364	10	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:26	TIEVTPALIF	0.6789	0.9364	10	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B44:13	TIEVTPALIF	0.6789	0.9364	10	20
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-B67:01	DPTIEVTPAL	0.6352	0.7489	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A69:01	DPTIEVTPAL	0.5052	0.5394	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A25:01	DPTIEVTPAL	0.4885	0.8218	8	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C04:03	FVDEYDPTIEV	1	0.686	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C05:01	FVDEYDPTIEV	1	0.9542	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C08:02	FVDEYDPTIEV	1	0.9637	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:06	FVDEYDPTIEV	0.9992	0.6139	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A02:03	FVDEYDPTIEV	0.9959	0.5868	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A68:02	FVDEYDPTIEV	0.9912	0.5754	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A69:01	FVDEYDPTIEV	0.9902	0.7275	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C17:01	FVDEYDPTIEV	0.9861	0.9703	3	14
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-A69:01	YDPTIEVTPAL	0.9653	0.545	7	18
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	HLA-C08:01	FVDEYDPTIEV	0.8454	0.9727	3	14

Top

Potential FusionNeoAntigen Information of KRAS-SLC2A14 in HLA II

KRAS-SLC2A14_25398208_7985410.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-0704	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-0819	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1201	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1201	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1201	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1203	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1203	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1205	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1205	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1205	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1206	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1206	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1206	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1207	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1207	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1207	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1208	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1208	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1208	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1210	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1210	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1210	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1211	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1211	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1211	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1212	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1212	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1214	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1214	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1214	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1217	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1217	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1217	EYDPTIEVTPALIFA	6	21
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1222	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1222	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1377	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1428	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1428	YDPTIEVTPALIFAI	7	22
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1431	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1439	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1448	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1450	DPTIEVTPALIFAIT	8	23
KRAS-SLC2A14	chr12	25398208	chr12	7985410	175	DRB1-1450	YDPTIEVTPALIFAI	7	22

Top

Fusion breakpoint peptide structures of KRAS-SLC2A14

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2257	EYDPTIEVTPALIF	KRAS	SLC2A14	chr12	25398208	chr12	7985410	175

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of KRAS-SLC2A14

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	2257	EYDPTIEVTPALIF	-7.9962	-8.1096
HLA-B14:02	3BVN	2257	EYDPTIEVTPALIF	-5.70842	-6.74372
HLA-B52:01	3W39	2257	EYDPTIEVTPALIF	-6.83737	-6.95077
HLA-B52:01	3W39	2257	EYDPTIEVTPALIF	-4.4836	-5.5189
HLA-A11:01	4UQ2	2257	EYDPTIEVTPALIF	-10.0067	-10.1201
HLA-A11:01	4UQ2	2257	EYDPTIEVTPALIF	-9.03915	-10.0745
HLA-A24:02	5HGA	2257	EYDPTIEVTPALIF	-6.56204	-6.67544
HLA-A24:02	5HGA	2257	EYDPTIEVTPALIF	-5.42271	-6.45801
HLA-B44:05	3DX8	2257	EYDPTIEVTPALIF	-7.85648	-8.89178
HLA-B44:05	3DX8	2257	EYDPTIEVTPALIF	-5.3978	-5.5112
HLA-A02:01	6TDR	2257	EYDPTIEVTPALIF	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of KRAS-SLC2A14

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
KRAS-SLC2A14	chr12	25398208	chr12	7985410	10	20	TIEVTPALIF	ACAATAGAGGTCACCCCAGCTCTGATCTTT
KRAS-SLC2A14	chr12	25398208	chr12	7985410	11	20	IEVTPALIF	ATAGAGGTCACCCCAGCTCTGATCTTT
KRAS-SLC2A14	chr12	25398208	chr12	7985410	11	21	IEVTPALIFA	ATAGAGGTCACCCCAGCTCTGATCTTTGCC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	3	14	FVDEYDPTIEV	TTTGTGGACGAATATGATCCAACAATAGAGGTC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	4	14	VDEYDPTIEV	GTGGACGAATATGATCCAACAATAGAGGTC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	5	14	DEYDPTIEV	GACGAATATGATCCAACAATAGAGGTC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	5	15	DEYDPTIEVT	GACGAATATGATCCAACAATAGAGGTCACC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	5	16	DEYDPTIEVTP	GACGAATATGATCCAACAATAGAGGTCACCCCA
KRAS-SLC2A14	chr12	25398208	chr12	7985410	6	14	EYDPTIEV	GAATATGATCCAACAATAGAGGTC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	7	18	YDPTIEVTPAL	TATGATCCAACAATAGAGGTCACCCCAGCTCTG
KRAS-SLC2A14	chr12	25398208	chr12	7985410	8	17	DPTIEVTPA	GATCCAACAATAGAGGTCACCCCAGCT
KRAS-SLC2A14	chr12	25398208	chr12	7985410	8	18	DPTIEVTPAL	GATCCAACAATAGAGGTCACCCCAGCTCTG
KRAS-SLC2A14	chr12	25398208	chr12	7985410	9	18	PTIEVTPAL	CCAACAATAGAGGTCACCCCAGCTCTG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
KRAS-SLC2A14	chr12	25398208	chr12	7985410	6	21	EYDPTIEVTPALIFA	GAATATGATCCAACAATAGAGGTCACCCCAGCTCTGATCTTTGCC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	7	22	YDPTIEVTPALIFAI	TATGATCCAACAATAGAGGTCACCCCAGCTCTGATCTTTGCCATC
KRAS-SLC2A14	chr12	25398208	chr12	7985410	8	23	DPTIEVTPALIFAIT	GATCCAACAATAGAGGTCACCCCAGCTCTGATCTTTGCCATCACA

Top

Information of the samples that have these potential fusion neoantigens of KRAS-SLC2A14

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUAD	KRAS-SLC2A14	chr12	25398208	ENST00000256078	chr12	7985410	ENST00000340749	TCGA-75-5122-01A

Top

Potential target of CAR-T therapy development for KRAS-SLC2A14

Predicted 3D structure. We used RoseTTAFold.

245_KRAS-SLC2A14_2771d_pred.pdb

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

118_138

498.0

Transmembrane

Helical%3B Name%3D3

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

149_169

498.0

Transmembrane

Helical%3B Name%3D4

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

178_198

498.0

Transmembrane

Helical%3B Name%3D5

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

208_228

498.0

Transmembrane

Helical%3B Name%3D6

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

294_314

498.0

Transmembrane

Helical%3B Name%3D7

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

30_50

498.0

Transmembrane

Helical%3B Name%3D1

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

329_349

498.0

Transmembrane

Helical%3B Name%3D8

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

359_379

498.0

Transmembrane

Helical%3B Name%3D9

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

393_413

498.0

Transmembrane

Helical%3B Name%3D10

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

424_444

498.0

Transmembrane

Helical%3B Name%3D11

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

452_472

498.0

Transmembrane

Helical%3B Name%3D12

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000340749

89_109

498.0

Transmembrane

Helical%3B Name%3D2

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

118_138

521.0

Transmembrane

Helical%3B Name%3D3

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

149_169

521.0

Transmembrane

Helical%3B Name%3D4

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

178_198

521.0

Transmembrane

Helical%3B Name%3D5

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

208_228

521.0

Transmembrane

Helical%3B Name%3D6

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

294_314

521.0

Transmembrane

Helical%3B Name%3D7

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

30_50

521.0

Transmembrane

Helical%3B Name%3D1

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

329_349

521.0

Transmembrane

Helical%3B Name%3D8

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

359_379

521.0

Transmembrane

Helical%3B Name%3D9

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

393_413

521.0

Transmembrane

Helical%3B Name%3D10

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

424_444

521.0

Transmembrane

Helical%3B Name%3D11

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

452_472

521.0

Transmembrane

Helical%3B Name%3D12

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000396589

89_109

521.0

Transmembrane

Helical%3B Name%3D2

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

118_138

498.0

Transmembrane

Helical%3B Name%3D3

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

149_169

498.0

Transmembrane

Helical%3B Name%3D4

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

178_198

498.0

Transmembrane

Helical%3B Name%3D5

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

208_228

498.0

Transmembrane

Helical%3B Name%3D6

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

294_314

498.0

Transmembrane

Helical%3B Name%3D7

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

30_50

498.0

Transmembrane

Helical%3B Name%3D1

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

329_349

498.0

Transmembrane

Helical%3B Name%3D8

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

359_379

498.0

Transmembrane

Helical%3B Name%3D9

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

393_413

498.0

Transmembrane

Helical%3B Name%3D10

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

424_444

498.0

Transmembrane

Helical%3B Name%3D11

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

452_472

498.0

Transmembrane

Helical%3B Name%3D12

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000431042

89_109

498.0

Transmembrane

Helical%3B Name%3D2

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

118_138

162.0

Transmembrane

Helical%3B Name%3D3

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

149_169

162.0

Transmembrane

Helical%3B Name%3D4

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

178_198

162.0

Transmembrane

Helical%3B Name%3D5

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

208_228

162.0

Transmembrane

Helical%3B Name%3D6

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

294_314

162.0

Transmembrane

Helical%3B Name%3D7

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

30_50

162.0

Transmembrane

Helical%3B Name%3D1

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

329_349

162.0

Transmembrane

Helical%3B Name%3D8

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

359_379

162.0

Transmembrane

Helical%3B Name%3D9

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

393_413

162.0

Transmembrane

Helical%3B Name%3D10

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

424_444

162.0

Transmembrane

Helical%3B Name%3D11

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

452_472

162.0

Transmembrane

Helical%3B Name%3D12

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000542505

89_109

162.0

Transmembrane

Helical%3B Name%3D2

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

118_138

521.0

Transmembrane

Helical%3B Name%3D3

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

149_169

521.0

Transmembrane

Helical%3B Name%3D4

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

178_198

521.0

Transmembrane

Helical%3B Name%3D5

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

208_228

521.0

Transmembrane

Helical%3B Name%3D6

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

294_314

521.0

Transmembrane

Helical%3B Name%3D7

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

30_50

521.0

Transmembrane

Helical%3B Name%3D1

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

329_349

521.0

Transmembrane

Helical%3B Name%3D8

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

359_379

521.0

Transmembrane

Helical%3B Name%3D9

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

393_413

521.0

Transmembrane

Helical%3B Name%3D10

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

424_444

521.0

Transmembrane

Helical%3B Name%3D11

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

452_472

521.0

Transmembrane

Helical%3B Name%3D12

Tgene

SLC2A14

chr12:25398208

chr12:7985410

ENST00000543909

89_109

521.0

Transmembrane

Helical%3B Name%3D2

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene	Hchr	Hbp	Henst	Tgene	Tchr	Tbp	Tenst	DeepLoc result
KRAS	chr12	25398208	ENST00000256078	SLC2A14	chr12	7985410	ENST00000340749

Top

Related Drugs to KRAS-SLC2A14

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to KRAS-SLC2A14

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)